Literature DB >> 12456677

beta 1 Integrin-dependent cell adhesion to EMILIN-1 is mediated by the gC1q domain.

Paola Spessotto1, Marta Cervi, Maria Teresa Mucignat, Gabriella Mungiguerra, Ida Sartoretto, Roberto Doliana, Alfonso Colombatti.   

Abstract

EMILIN-1 (Elastin Microfibril Interface Located ProteIN), the prototype of the EMILIN family, consists of a cysteine-rich domain (EMI domain) at the N terminus, an extended region with a high potential coiled-coil structure, a short collagenous stalk, and a self-interacting globular gC1q-l domain. EMILIN-1 is an adhesive extracellular matrix constituent associated with elastic fibers, detected also in the proximity of cell surfaces. To localize the cell attachment site(s), monoclonal antibodies (mAbs) against EMILIN-1 or the gC1q-1 domain were used to inhibit cell attachment to EMILIN-1. Thus, one mAb mapping to the gC1q-1 domain caused complete inhibition of cell attachment. EMILIN-1 and gC1q-1 displayed a comparable dose-dependent ability to promote cell adhesion. Adhesion kinetics was similar to that of fibronectin (FN), reaching the maximum level of attachment at 20 min, but in the absence of cations adhesion was negligible. The relative adhesion strength to detach 50% of the cells was similar for EMILIN-1 and gC1q-1 (250-270 x g) but lower than that for FN (>>500). Cell adhesion to EMILIN-1 or gC1q-1 was completely blocked by a function-blocking beta(1) integrin subunit mAb. In contrast, adhesion to the complement C1q component was totally unaffected. Among the various function-blocking mAbs against the alpha integrin subunits only the anti-alpha(4) fully abrogated cell adhesion to gC1q-1 and up to 70% to EMILIN-1. Furthermore, only K562 cells transfected with the alpha(4) integrin chain, but not wild type K562, were able to adhere to EMILIN-1 and were specifically inhibited by anti-alpha(4) function-blocking mAb. Finally, cells attached to EMILIN-1 or gC1q-1, compared with cells plated on FN or vitronectin, which appeared well spread out on the substrate with prominent stress fibers and focal contacts, were much smaller with wide ruffles and a different organization status of the actin cytoskeleton along the cell periphery. This pattern was in accord with the ability of EMILIN-1 to promote cell movement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456677     DOI: 10.1074/jbc.M208322200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  EMILIN-1 deficiency induces elastogenesis and vascular cell defects.

Authors:  Miriam Zanetti; Paola Braghetta; Patrizia Sabatelli; Isabella Mura; Roberto Doliana; Alfonso Colombatti; Dino Volpin; Paolo Bonaldo; Giorgio M Bressan
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

2.  Sequence-specific backbone NMR assignments for the C-terminal globular domain of EMILIN-1.

Authors:  Giuliana Verdone; Simon A Colebrooke; Jonathan Boyd; Paolo Viglino; Alessandra Corazza; Roberto Doliana; Gabriella Mungiguerra; Alfonso Colombatti; Gennaro Esposito; Iain D Campbell
Journal:  J Biomol NMR       Date:  2004-05       Impact factor: 2.835

3.  EMILIN-3, peculiar member of elastin microfibril interface-located protein (EMILIN) family, has distinct expression pattern, forms oligomeric assemblies, and serves as transforming growth factor β (TGF-β) antagonist.

Authors:  Alvise Schiavinato; Ann-Kathrin A Becker; Miriam Zanetti; Diana Corallo; Martina Milanetto; Dario Bizzotto; Giorgio Bressan; Marija Guljelmovic; Mats Paulsson; Raimund Wagener; Paola Braghetta; Paolo Bonaldo
Journal:  J Biol Chem       Date:  2012-02-10       Impact factor: 5.157

4.  NMR-based homology model for the solution structure of the C-terminal globular domain of EMILIN1.

Authors:  Giuliana Verdone; Alessandra Corazza; Simon A Colebrooke; Daniel Cicero; Tommaso Eliseo; Jonathan Boyd; Roberto Doliana; Federico Fogolari; Paolo Viglino; Alfonso Colombatti; Iain D Campbell; Gennaro Esposito
Journal:  J Biomol NMR       Date:  2008-11-21       Impact factor: 2.835

5.  Differential regulation of the attachment of Kaposi's sarcoma-associated herpesvirus (KSHV)-infected human B cells to extracellular matrix by KSHV-encoded gB and cellular alphaV integrins.

Authors:  Ossie F Dyson; Telisha L Oxendine; Khalief E Hamden; Patrick W Ford; Shaw M Akula
Journal:  Cell Microbiol       Date:  2008-03-25       Impact factor: 3.715

Review 6.  Cross talk among TGF-β signaling pathways, integrins, and the extracellular matrix.

Authors:  John S Munger; Dean Sheppard
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-11-01       Impact factor: 10.005

7.  EMILIN1/α9β1 integrin interaction is crucial in lymphatic valve formation and maintenance.

Authors:  Carla Danussi; Lisa Del Bel Belluz; Eliana Pivetta; Teresa Maria Elisa Modica; Andres Muro; Bruna Wassermann; Roberto Doliana; Patrizia Sabatelli; Alfonso Colombatti; Paola Spessotto
Journal:  Mol Cell Biol       Date:  2013-09-09       Impact factor: 4.272

8.  Cyclic nucleotide-gated channel α-3 (CNGA3) interacts with stereocilia tip-link cadherin 23 + exon 68 or alternatively with myosin VIIa, two proteins required for hair cell mechanotransduction.

Authors:  Dakshnamurthy Selvakumar; Marian J Drescher; Dennis G Drescher
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

9.  SCAI acts as a suppressor of cancer cell invasion through the transcriptional control of beta1-integrin.

Authors:  Dominique T Brandt; Christian Baarlink; Thomas M Kitzing; Elisabeth Kremmer; Johanna Ivaska; Peter Nollau; Robert Grosse
Journal:  Nat Cell Biol       Date:  2009-04-06       Impact factor: 28.824

Review 10.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.